Institut Gustave Roussy

49 trials 30 recruiting Academic / non-commercial

Filter these 49 trials by condition, phase, country and more.

Open in Search →

49 Registered trials

30 Recruiting

16 Completed trials

15 Countries active

74 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 15 Phase II: 24 Phase I/II: 5 Phase IV: 1 Phase I (Other): 2 Phase I (FiH): 2

Oversight events:

1 serious breach across 1 trial

View oversight register →

100%

16 of 16 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 4 Head and neck cancer 2 Triple negative breast cancer 2 Rectal adenocarcinoma 2 Lung squamous cell carcinoma metastatic 1 Oesophageal squamous cell carcinoma metastatic 1 Squamous cell carcinoma of the cervix 1 Brain stem glioma 1 Colorectal cancer 1 Germ cell cancer 1 HER2 positive breast cancer 1 Squamous cell carcinoma of head and neck 1

Top IMPs

NIVOLUMAB 5 PEMBROLIZUMAB 5 ATEZOLIZUMAB 4 CISPLATIN 4 CARBOPLATIN 3 IPILIMUMAB 3 TEMOZOLOMIDE 3 BEVACIZUMAB 2 CABOZANTINIB 2 CANNABIDIOL 2 CAPECITABINE 2 CEMIPLIMAB 2

All trials — page 3

49 total

Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc… Ended

2024-515533-15-00 Phase II 1 country ATEZOLIZUMAB

Showing 49–49 of 49 trials

← All sponsors A–Z